Lakefront Biotherapeutics NV
LKFT evidence brief
What we can confirm
- Market Cap:
- $1.81B
What it means
What to watch
Prepared research question
What matters most for LKFT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LKFT
Lakefront Biotherapeutics NV (LKFT) is a biotechnology company repositioning itself through a strategic wind-down of its cell therapy business and a focus on business development to rebuild its pipeline, with a single remaining clinical-stage asset, GLPG3667, and a cash reserve of $40.0M as of 2025-12-31 [sec].
Key risk: Single-asset pipeline risk
Market Cap
$1.81B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Tracking 30 clinical trials for Lakefront Biotherapeutics NV.
Lakefront Biotherapeutics NV (LKFT) is a biotechnology company repositioning itself through a strategic wind-down of its cell therapy business and a focus on business development to rebuild its pipeline, with a single remaining clinical-stage asset, GLPG3667, and a cash reserve of $40.0M as of 2025-12-31 [sec].
- Cash & equivalents of $40.0M as of 2025-12-31 [sec].
- Only remaining clinical-stage program is GLPG3667, a TYK2 inhibitor in Phase 2 for dermatomyositis (DM) and systemic lupus erythematosus (SLE) [sec · filed 2026-03-26].
- Board of Directors decided in January 2026 to wind down cell therapy activities, impacting ~365 employees and closing sites in Europe, U.S., and China [sec · filed 2026-03-26].
- Ongoing royalty streams and earn-outs from Jyseleca® expected into the mid-2030s [sec · filed 2026-03-26].
- Long-standing partnership with Gilead, which owns >25% of equity, is a key enabler of business development strategy [sec · filed 2026-03-26].
What works
- Strong cash position of $40.0M as of 2025-12-31 provides runway for business development [sec].
- Ongoing royalty streams from Jyseleca® provide additional cash inflows into the mid-2030s [sec · filed 2026-03-26].
- Long-standing partnership with Gilead, a major shareholder (>25% equity), supports business development and provides strategic alignment [sec · filed 2026-03-26].
- Modality-agnostic asset selection approach allows flexibility in pursuing diverse opportunities (biologics, bispecifics, ADCs, small molecules) [sec · filed 2026-03-26].
What to weigh
- Pipeline is reduced to a single clinical-stage asset (GLPG3667) after wind-down of cell therapy and discontinuation of small molecule discovery [sec · filed 2026-03-26].
- Wind-down of cell therapy activities involves significant workforce reduction (~365 employees) and site closures, with associated execution risks [sec · filed 2026-03-26].
- Company will require substantial additional capital to acquire or develop new product candidates and complete clinical development [sec · filed 2026-03-26].
- GLPG3667 may not advance to Phase 3 or be commercialized; any delay or setback could adversely affect the business [sec · filed 2026-03-26].
From the filings
Quoted directly from source documents.
Wind-down of cell therapy activities decided in January 2026
“Board of Directors decided in January 2026 to initiate the wind-down of the cell therapy activities.”
SEC filings · March 26, 2026
Only remaining clinical-stage program is GLPG3667
“our only product candidate in development will be GLPG3667.”
SEC filings · March 26, 2026
Gilead owns more than 25% of equity
“As a major shareholder owning more than 25% of our equity, Gilead provid”
SEC filings · March 26, 2026
Risks & what to watch (4)›
Key risks
- Single-asset pipeline risk — With only GLPG3667 in development, failure or delay of this program would leave the company without any clinical-stage assets [sec · filed 2026-03-26].
- Execution risk of wind-down — Wind-down of cell therapy activities may not be completed timely or on favorable terms, with ~365 employees impacted [sec · filed 2026-03-26].
- Capital needs for pipeline rebuild — Substantial additional capital required to acquire/develop new candidates; current cash may not suffice [sec · filed 2026-03-26].
- Dependence on Gilead partnership — Heavy reliance on Gilead as major shareholder and partner; any change in relationship could impact strategy [sec · filed 2026-03-26].
What to watch
- Progress of GLPG3667 Phase 2 trials in DM and SLE, and any partnership or business development decisions regarding this asset [sec · filed 2026-03-26].
- Completion of cell therapy wind-down and associated cost savings, including site closures and workforce reduction [sec · filed 2026-03-26].
- Execution of business development strategy to acquire or partner new product candidates, especially in oncology and immunology [sec · filed 2026-03-26].
- Cash runway and any additional financing needs as the company pursues transformational transactions [sec · filed 2026-03-26].
Sources: SEC filings · Generated October 12, 2026 · How we verify sources →
Run Lakefront Biotherapeutics NV through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Lakefront Biotherapeutics NV facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 3.4%
- Days to cover
- 7.0
- Shares short
- 1,371,531
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LKFT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Lakefront Biotherapeutics NV?
Lakefront Biotherapeutics NV (LKFT) is a biotechnology company repositioning itself through a strategic wind-down of its cell therapy business and a focus on business development to rebuild its pipeline, with a single remaining clinical-stage asset, GLPG3667, and a cash reserve of $40.0M as of 2025-12-31 [sec].
Who is the CEO of Lakefront Biotherapeutics NV?
Mr. Henry O. Gosebruch is the chief executive officer of Lakefront Biotherapeutics NV (LKFT).
Where is Lakefront Biotherapeutics NV headquartered?
Lakefront Biotherapeutics NV (LKFT) is headquartered in Mechelen, Belgium.
What therapeutic areas does Lakefront Biotherapeutics NV focus on?
Lakefront Biotherapeutics NV develops therapies across Immunology, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.